PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22871995-0	2012	In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.	Tacrolimus	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14	
22871995-1	2012	Tacrolimus is metabolized by CYP3A4 and CYP3A5 and is characterized by a narrow therapeutic index and highly variable pharmacokinetics.	Tacrolimus	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	29-35	
22871995-3	2012	In vivo CYP3A4 activity and CYP3A5 genotype explain 56-59% of variability in tacrolimus dose requirements and clearance, contributing ~25 and 30%, respectively.	Tacrolimus	77-87	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	8-14	
22871995-5	2012	These data indicate that CYP3A4- and CYP3A5-mediated tacrolimus metabolisms are major determinants of tacrolimus disposition in vivo and explain a substantial part of the clinically observed high interindividual variability in tacrolimus pharmacokinetics.	Tacrolimus	53-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31	
22871995-5	2012	These data indicate that CYP3A4- and CYP3A5-mediated tacrolimus metabolisms are major determinants of tacrolimus disposition in vivo and explain a substantial part of the clinically observed high interindividual variability in tacrolimus pharmacokinetics.	Tacrolimus	102-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31	
22871995-5	2012	These data indicate that CYP3A4- and CYP3A5-mediated tacrolimus metabolisms are major determinants of tacrolimus disposition in vivo and explain a substantial part of the clinically observed high interindividual variability in tacrolimus pharmacokinetics.	Tacrolimus	102-112	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-31